SPRUCE BIOSCIENCES, INC. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 72/100
What the filing says
Spruce Biosciences raised $5.5M via private stock purchase (Regulation D Rule 506(b)) from Cure Sanfilippo Foundation and National MPS Society (unspecified amounts per purchaser; Exhibit A redacted). Adrian Quartel hired as Chief Medical Officer effective July 27, 2026, at $512,300 annual base salary plus 40% target bonus and 13,000 RSU award vesting over four years. Proceeds designated exclusively for expanded-access enzyme replacement drug substance and product manufacturing.
Why this rating
Capital raise equals 196% of $2.8M market cap—highly material. Expands cash for clinical program. CMO hire is substantive leadership addition. However, small absolute investor base and lack of transparency on individual subscription amounts limit clarity.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.